Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Succinyl-CoA:3-oxoacid CoA transferase 1 (OXCT1) is a mitochondrial enzyme that catalyzes the reversible transfer of coenzyme A from succinyl-CoA to acetoacetate, forming acetoacetyl-CoA. This reaction constitutes the first, rate-limiting step in the extrahepatic catabolism of ketone bodies (ketolysis), enabling tissues such as heart, brain, and kidney to utilize ketones as energy sources during fasting, illness, or exercise. OXCT1 is absent from the liver, distinguishing tissue-specific roles in ketogenesis and ketolysis. Mutations in OXCT1 can result in succinyl-CoA:3-oxoacid CoA transferase deficiency, a metabolic disorder characterized by episodes of severe ketoacidosis. OXCT1 is also implicated in diabetes—where its activity is reduced in pancreatic islets—and in tumor metabolism, where its function may provide proliferating cancer cells with an alternative energy source
Inhibition may impair ketone body utilization and energy metabolism; potential for tumor metabolic targeting
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Succinyl-CoA:3-oxoacid CoA transferase 1 (OXCT1).